New malaria combo shows promise in clearing parasite
NCT ID NCT07235033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria parasite from the blood by day 29 without the infection coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Libreville, BP 1437, Gabon
-
Novartis Investigative Site
Ahero, 40100, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.